As GLP-1 RA use soars, experts are worried that patients may not be getting the right nutrients in their diets. How can ...

With three meds approved for weight management and several on the way, these may make a dent in the obesity epidemic.

PRNewswire/ -- (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today ...

Adverse events were frequent, and most were gastrointestinal-related, including nausea, vomiting, diarrhea, constipation ...

Topline data were announced from a phase 3 trial evaluating CagriSema in overweight or obese patients without type 2 diabetes.

The FDA has approved Zepbound (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea in adults with obesity.

The best semaglutide dose for weight loss varies according to your starting weight, risks, and stage of treatment. Read to ...

Hangzhou Sciwind Biosciences Co., a pre-commercial biopharmaceutical company focusing on developing innovative therapies to treat metabolic diseases, today announced a licensing and collaboration ...

For overweight or obese individuals without diabetes, but with pre-existing cardiovascular disease, semaglutide (Ozempic, ...

We recently published a list of 10 Best Blue Chip Stocks to Buy for 2025. In this article, we are going to take a look at ...

With nutritional, pharmaceutical, and surgical options available for obesity, clinicians are being called upon to make ...

Dec. 18, 2024 — Researchers studied oxygen treatment as a potential therapy to target specific cells linked to the development of cardiovascular and metabolic disorders like high blood pressure ...